KYNB (Biotechnology) Stock Valuation & Fair Value Significantly overvalued
KYNB (Biotechnology) trades at a blended P/E of 0.7, about 258% above its historical normal valuation, with a forward growth estimate of -61.0% and a PEG of —. Analysts' one-year estimates have been hit 18% of the time.
No quality score is published for this company, which is normal for insurers, banks and REITs. This rating reflects valuation, forecast return and analyst accuracy only. Ratings that cite business quality require one.
Valuation flags
- Overvalued by 258%
- Negative growth forecast
Frequently asked questions
Is KYNB overvalued?
At a blended P/E of 0.7 versus its historical normal P/E of 0.2, KYNB trades about 258% above its typical valuation. tickerseer currently rates it significantly overvalued.
What is KYNB's fair value and PEG?
KYNB trades at a blended P/E of 0.7 against a historical normal P/E of 0.2, and a forward growth estimate of -61.0%.
Has tickerseer's rating of KYNB changed?
tickerseer's rating has been significantly overvalued since 2026-08-07.
Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. Educational content, not investment advice.